Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial

Anne-Sophie Defachelles,Emilie Bogart,Michela Casanova,Johannes H. M. Merks,Gianni Bisogno,Giuseppina Calareso,Soledad Gallego Melcon,Susanne A. Gatz,Marie-Cécile Le Deley,Kieran McHugh,Alicia Probst,Nathalie Rocourt,Rick R. van Rijn,Keith Wheatley,Veronique Minard-Colin,Julia Chisholm

Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial

2021

Anne-Sophie Defachelles
Emilie Bogart
Michela Casanova
Johannes H. M. Merks
Gianni Bisogno
Giuseppina Calareso
Soledad Gallego Melcon
Susanne A. Gatz
Marie-Cécile Le Deley
Kieran McHugh
Alicia Probst
Nathalie Rocourt
Rick R. van Rijn
Keith Wheatley
Veronique Minard-Colin
Julia Chisholm

PURPOSEThe VIT-0910 trial was conducted to evaluate efficacy and safety of the vincristine-irinotecan combination with and without temozolomide (VIT and VI, respectively) in relapsed or refractory ...

Keywords:

Temozolomide
Irinotecan
Cancer
Innovative Therapies
Medicine
Oncology
Refractory
Internal medicine
Rhabdomyosarcoma
Soft tissue sarcoma
Vincristine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations